title: Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen.
authors.affiliation: Department of Hematology, Institute of Hematology and Transfusion Medicine , Warsaw , Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Jamroziak
authors.forename: Janusz
authors.initials: J
authors.lastname: Szemraj
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
authors.forename: Andrzej
authors.initials: A
authors.lastname: Tukiendorf
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Giannopoulos
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010447:Peptide Hydrolases / Q000235:genetics*; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome; D044767:Ubiquitin-Protein Ligases; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C502543:CRBN protein, human; D013792:Thalidomide; D044767:Ubiquitin-Protein Ligases; D010447:Peptide Hydrolases; D014740:Vidarabine; C024352:fludarabine